
Kinnate Biopharma touts early efficacy in pan-RAF program: #AACR23
ORLANDO — After suffering two delays last year, Kinnate Biopharma is offering an early-stage look at its monotherapy pan-RAF inhibitor, while deprioritizing a preclinical program to hone in on more advanced programs.
Currently available RAF inhibitors such as Novartis’ Tafinlar, Pfizer’s Braftovi and Roche’s Zelboraf target class I BRAF kinase mutations. Kinnate’s exarafenib, on the other hand, was designed to also target class II and III mutations, which constitute roughly 55% of oncogenic BRAF mutations, according to the company.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.